Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.

＞98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

咪喹莫特；R 837

白色或类白色结晶性粉末

DMSO : 1.2 mg/mL (5 mM), with gentle warming

Toll-like Receptor (TLR)

In animal models, imiquimod stimulates the innate immune response by increasing NK cell activity, activating macrophages to secretecytokines and nitric oxide, and inducing proliferation and differentiation of B lymphocytes. Imiquimod stimulates the innate immune response through induction, synthesis, and release of cytokines, including interferon-a (IFN-α), interleukin (IL)-6, and tumour necrosis factor (TNF)-α.

1. Gibson SJ, et al. Cell Immunol. 2002 Jul-Aug;218(1-2):74-86.

2. Akira S, Hemmi H. Immunol Lett. 2003 Jan 22;85(2):85-95.

3. Otero M, et al. Vaccine. 2004 Apr 16;22(13-14):1782-90.